Introducing Cas-CLOVER: The clean alternative to CRISPR/Cas9
Demeetra, is a gene editing technologies company with an excellent track-record of supporting cell line development (CLD) and bioprocessing programs. As a spin-out of Transposagen, we introduced the piggyBac transposase which was quickly adopted by Big Pharma and exclusively licensed to Lonza. Now we are offering Cas-CLOVER, “the clean alternative to CRISPR/Cas9” for CLD in CHO, HEK293 and more. In her BPI presentation “High-throughput gene editing of CHO-K1 cells using Cas-CLOVER” on 9/20/21 Tiffany McLamarrah our collaborator from Sanofi will present her work in editing 30 individual CHO-K1 cell lines in just months. Cas-CLOVER has demonstrated higher fidelity than CRISPR/Cas9, meaning less off-targets. Commercial FTO in a single license, and royalty free options are available. Join us to learn about a cleaner more economical gene editing process.
Brands: Cas-CLOVER licensing model options: 1- one-time payment, unlimited targets, no royalties. 2- pay per use. We offer target design and CLD services for proof-of-concept support.